Immunomedics Announces Orphan Drug Designation for Veltuzumab for the ...
Immunomedics also has a number of other product candidates that target solid tumors and hematologic malignancies, as well as other diseases, in various stages of clinical and pre-clinical development. These include bispecific antibodies targeting ...
Nasdaq - Fri, 21 Nov 2014 05:30

12 Reasons to Get Angry about the Gates Foundation's Latest Project to ...
A shot too inhumane to give violent sex offenders, but just fine for women living in the "Third World"? Susan E. Wills (62). Susan E. Wills. SHARES. COMMENTS. First one is free... so are the rest. Daily. By submitting above you agree the Aleteia ...
Aleteia - Thu, 20 Nov 2014 21:05

Gilead Sciences, Inc. (GILD), Biogen Idec Inc (BIIB), Bristol-Myers Squibb Co ...
Biogen Idec Inc (NASDAQ:BIIB) is a biotechnology company that discovers, develops, and supplies therapies for people living with neurodegenerative diseases, hematologic conditions and autoimmune disorders. Credit Suisse has downgraded the stock's ...
StockWise Daily - Fri, 21 Nov 2014 10:22

Latest Updates on MacroGenics Inc. (NASDAQ:MGNX)
MacroGenics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. ... tumors, including breast, gastroesophageal, bladder ...
Inside Trade - Fri, 21 Nov 2014 07:29

Has Alexion Pharmaceuticals Healed From Its Bad Break?
Today we'll check in on Alexion Pharmaceuticals (NASDAQ:ALXN), which develops therapeutics to treat hematologic and neurologic diseases and metabolic and inflammatory disorders. Its first commercial product, Soliris, comes with a hefty price tag of ...
Investor's Business Daily - Thu, 20 Nov 2014 11:30

News Reports: Alexion Pharmaceuticals, Inc. (ALXN), Canadian Imperial Bank of ...
WallStreet Scope - Thu, 20 Nov 2014 14:52



Two Drugs are No More Effective Than One to Treat Common Kidney Disease
“The HALT-PKD studies were well performed and the largest of their kind,” said Robert Star, M.D., director of the Division of Kidney, Urologic, and Hematologic Diseases within NIDDK. “More research is needed to better understand how polycystic kidney ...
eNews Park Forest - Sat, 15 Nov 2014 06:26

Leading Health Care Stock for Small-Cap Stars is Geron Corp. (GERN) for ...
... a 50-day SMA of $2.29, and a 200-day SMA of $2.60. Geron Corp is a clinical stage biopharmaceutical company engaged in the discovery and development of therapeutic products for oncology such as telomerase inhibitor, imetelstat and in hematologic ...
Equities.com - Fri, 21 Nov 2014 13:45

Portola Pharmaceuticals to Present at the Credit Suisse 2014 Healthcare ...
Portola Pharmaceuticals is a biopharmaceutical company developing product candidates that could significantly advance the fields of thrombosis and other hematologic diseases. The Company is advancing its three wholly-owned programs using novel ...
Nasdaq - Thu, 06 Nov 2014 05:12


1  2  3  4  5  6  7  8    ->


We do not evaluate or guarantee the accuracy of any content in this site. Click here for the full disclaimer.

Last update: September 2014